EUVIMEDEUVIMED entdecken
Crossref

Celastrol, which targets IL-2/CD25 binding inhibition, induces T cell-mediated antitumor activity in melanoma

Okki Cho, Joong-Woon Lee, Young-Jin Jeong, Lee Kyung Kim, Bo-Kyung Jung, Tae-Hwe Heo

European Journal of Pharmacology · 2024

DOI: 10.1016/j.ejphar.2023.176239 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmacology, 2024. Verfasst von Okki Cho und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Pharmacoimmunology, Integrated Research Institute of Pharmaceutical Sciences and BK21 FOUR Team for Advanced Program for SmartPharma Le…. Hauptthemen laut MEDLINE: Melanoma. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Ministry of Education, Science and Technology, Catholic University of Korea, National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Interleukin-2 (IL-2) induces contrasting immune responses depending on its binding receptor subunit; thus, selective receptor binding is considered a key challenge in cancer therapeutic strategies. In this study, we aimed to investigate the inhibition of IL-2 action and antitumor activity of celastrol (CEL), a compound identified in a screen for IL-2/CD25 binding inhibitors, and to elucidate the underlying role of CEL in immune cells. We found that CEL selectively impairs the binding of IL-2 and CD25 and directly binds to IL-2 but not to CD25. CEL significantly suppressed the proliferation and signaling of IL-2-dependent murine T cells and interfered with IL-2-responsive STAT5 phosphorylation in IL-2 reporter cells and human PBMCs. After confirming the impact of CEL on IL-2, we evaluated its antitumor activity in C57BL/6 mice bearing B16F10 tumors and found that CEL significantly inhibited tumor growth by increasing CD8+ T cells. We also found that CEL did not inhibit tumor growth in T cell-deficient BALB/c nude mice, suggesting that its activity was mediated by the T-cell response. Moreover, combination therapy with low-dose CEL and a TNFR2 antagonist synergistically improved the therapeutic efficacy of the individual monotherapies by increasing the ratio of intratumoral CD8/Treg cells and suppressing Foxp3 expression. These findings suggest that CEL, which inhibits CD25 binding by targeting IL-2, exerts antitumor activity by mediating the T-cell response and could be a promising candidate for combination therapy in cancer immunotherapy against melanoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaHumansMiceAnimalsInterleukin-2CD8-Positive T-LymphocytesMice, NudeMice, Inbred C57BLInterleukin-2 Receptor alpha SubunitT-Lymphocytes, RegulatoryPentacyclic Triterpenes

Stichwörter der Autor:innen

Cancer immunotherapyCelastrolCombination therapyInterleukin-2Natural small moleculeTNFR2

Substanzen

Interleukin-2Interleukin-2 Receptor alpha SubunitcelastrolPentacyclic Triterpenes

Autor:innen und Institutionen

  • Laboratory of Pharmacoimmunology, Integrated Research Institute of Pharmaceutical Sciences and BK21 FOUR Team for Advanced Program for SmartPharma Leaders, College of Pharmacy, The Catholic University of Korea, 43 Jibon…

Förderung

  • Ministry of Education, Science and Technology
  • Catholic University of Korea
  • National Research Foundation of Korea

Zitieren

APA

Cho, O., Lee, J. W., Jeong, Y. J., Kim, L. K., Jung, B. K., & Heo, T. H. (2024). Celastrol, which targets IL-2/CD25 binding inhibition, induces T cell-mediated antitumor activity in melanoma. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2023.176239

Vancouver

Cho O, Lee JW, Jeong YJ, Kim LK, Jung BK, Heo TH. Celastrol, which targets IL-2/CD25 binding inhibition, induces T cell-mediated antitumor activity in melanoma. European Journal of Pharmacology. 2024. doi:10.1016/j.ejphar.2023.176239

BibTeX
@article{Cho2024,
  author = {Cho, Okki and Lee, Joong-Woon and Jeong, Young-Jin and Kim, Lee Kyung and Jung, Bo-Kyung and Heo, Tae-Hwe},
  title = {Celastrol, which targets IL-2/CD25 binding inhibition, induces T cell-mediated antitumor activity in melanoma},
  journal = {European Journal of Pharmacology},
  year = {2024},
  doi = {10.1016/j.ejphar.2023.176239}
}
Kostenlos starten →